Claims for Patent: 12,295,940

Summary for Patent: 12,295,940

Title:	Viral inhibitors, the synthesis thereof, and intermediates thereto
Abstract:	The present disclosure discloses compositions comprising maribavir, methods of providing the same, and compositions providing intermediates useful in providing maribavir. Maribavir (((2S,3S,4R,5S)-2-(5,6-dichloro-2-(isopropylamino)-1H-benzo[d]imidazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol) is a benzimidazole riboside and is an orally available antiviral medication against cytomegalovirus (CMV).
Inventor(s):	Jeffrey Scott DEPUE, Suresh Kumar Tipparaju, Helge Alfred REISCH, Datong Tang, Kishore Ramachandran
Assignee:	Takeda Pharmaceutical Co Ltd
Application Number:	US18/777,473
Patent Claims:	1. A composition of maribavir, Compound 2, and Compound 4, the composition comprising maribavir, Compound 2, and Compound 4, having the following structures: wherein Compound 2 is present in an amount of 0.1% w/w or less relative to maribavir and Compound 4 is present in an amount of 0.1% w/w or less relative to maribavir. 2. The composition of claim 1, wherein Compound 4 is present in an amount of from 0.01% to 0.1% w/w relative to maribavir. 3. The composition of claim 2, further comprising Compound 3, wherein Compound 3 is present in an amount of from 0.01% to 0.1% w/w relative to maribavir. 4. The composition of claim 3, wherein Compound 2 is present in an amount of from 0.01% to 0.1% w/w relative to maribavir. 5. The composition of claim 4, further comprising D-maribavir, wherein D-maribavir is present in an amount of 0.1% w/w or less relative to maribavir. 6. A pharmaceutical composition comprising a composition of claim 5 and one or more pharmaceutically acceptable excipients. 7. A pharmaceutical composition comprising a composition of claim 4 and one or more pharmaceutically acceptable excipients. 8. A pharmaceutical composition comprising a composition of claim 3 and one or more pharmaceutically acceptable excipients. 9. The composition of claim 2, wherein Compound 2 is present in an amount of from 0.01% to 0.1% w/w relative to maribavir. 10. A pharmaceutical composition comprising a composition of claim 2 and one or more pharmaceutically acceptable excipients. 11. The composition of claim 1, wherein Compound 4 is present in an amount of 0.05% w/w or less relative to maribavir. 12. The composition of claim 11, wherein Compound 4 is present in an amount of from 0.01% to 0.05% w/w relative to maribavir. 13. The composition of claim 1, further comprising Compound 3, wherein Compound 3 is present in an amount of 0.1% w/w or less relative to maribavir. 14. The composition of claim 1, further comprising D-maribavir, wherein D-maribavir is present in an amount of 0.1% w/w or less relative to maribavir. 15. The composition of claim 1, wherein the maribavir has a particle size distribution (PSD) with a d (50) of between about 170 and about 350 μm. 16. The composition of claim 15, wherein the d (50) is between about 170 and about 226 μm. 17. The composition of claim 15, wherein the d (50) is between about 227 and about 280 μm. 18. The composition of claim 15, wherein the d (50) is between about 281 and about 336 μm. 19. A pharmaceutical composition comprising a composition of claim 15 and one or more pharmaceutically acceptable excipients. 20. A pharmaceutical composition comprising a composition of claim 1 and one or more pharmaceutically acceptable excipients.